Targeted Strategies for Today's Evolving Markets

MissionIR Blog

NeuroVive Pharmaceutical AB (NEVPF) Starts Presentation at 2015 Marcum MicroCap Conference

NeuroVive Pharmaceutical AB is involved in the research and development of mitochondrial-protecting pharmaceuticals in Sweden and Hong Kong. The company’s product portfolio includes its drug candidate CicloMulsion, which is in phase 3 clinical study for cell protection against reperfusion injury during heart attack treatment; NeuroSTAT, a drug candidate that is in phase 2a clinical study for the treatment of traumatic brain injuries; and NVP019, an intravenous formulation that is in pre-clinical phase for treating myocardial infarct and traumatic brain injury. For more information, visit the company’s website at

The Marcum MicroCap Conference is a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The two-day 2016 conference will include feature presentations by CEOs and CFOs from seven principal industry sectors, expert panels moderated by industry leaders, and the opportunity to meet with management of presenting companies on a one-on-one basis. Marcum is partnered with KCSA Strategic Communications to present this year's Marcum MicroCap Conference.
This entry was posted in Marcum MicroCap. Bookmark the permalink.

Comments are closed.